Oncology

Tecentriq is the first anti-PDL1 cancer immunotherapy approved for metastatic non-small cell lung cancer.

Major pathological tumor regression was experienced by 40% of patients receiving neoadjuvant immunotherapy before resection.

Tecentriq provides new option for patients with previously treated metastatic lung cancer.

Nivolumab prior to tumor resection found safe in patients with early non-small cell lung cancer.

Tecentriq is the first anti-PDL1 cancer immunotherapy approved for metastatic non-small cell lung cancer.

Niraparib significantly improved outcomes of platinum-sensitive recurrent ovarian cancer in landmark trial.

Atezolizumab is a PD-L1 inhibitor that uses the immune system to fight cancer.

A unique pattern of motion by repair proteins allows them to rapidly scan long DNA and flag repair machinery in condition that can lead to skin cancer.

Despite widespread criticism, the United States may be paying less for hepatitis c virus drugs than other developed countries.

Top news of the week from The American Journal of Pharmacy Benefits.

Top news of the week in oncology, and cancer drug development.

Intervention programs may reduce the consumption of sugar, particularly in young males and cervical cancer survivors.

Results from a phase 3 trial demonstrates that nintedanib improved progression-free survival, but not overall survival in colon cancer patients.

Top news of the day from across the health care landscape.

Atezolizumab is a PD-L1 inhibitor designed to use the body’s own immune system to fight cancer.

Atezolizumab demonstrated significant improvement in survival compared with docetaxel in individuals with non-small cell lung cancer.

Premenopausal, overweight women have a decreased risk of breast cancer, while postmenopausal women have an increased risk.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

With the high number of oral therapies hitting the market, specialty pharmacies are now on the frontline of cancer treatment.

A general lack of knowledge for symptoms of cancer linked to regions where cancer survival is worse.

Novartis presented results from clinical trials of Zykadia at the European Society of Medical Oncology Congress.

Crizotinib-pre-treated patients with non-small cell lung cancer experienced superior survival rates compared with chemotherapy.

Adjuvant treatment with recombinant, human monoclonal antibody extended overall survival in patients with melanoma in a recent trial.

A health and exercise program may improve quality-of-life in patients recovering from bowel cancer.

Top news of the day from across the health care landscape.

LEE011 plus letrozole may prove to be effective first-line breast cancer therapy.

LEE011 plus letrozole demonstrates significant progression free survival in patients with breast cancer.